Protein detail
PK3CG
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PI3-kinase subunit gamma) (PI3K-gamma) (PI3Kgamma) (PtdIns-3-kinase subunit gamma) (EC 2.7.1.137) (EC 2.7.1.153) (EC 2.7.1.154) (Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma) (PtdIns-3-kinase subunit p110-gamma) (p110gamma) (Phosphoinositide-3-kinase catalytic gamma polypeptide) (Serine/threonine protein kinase PIK3CG) (EC 2.7.11.1) (p120-PI3K)
Entry name PK3CG | UniProt ID | EVMP confidence score 0.50 |
Supporting publications (n) 5 | Transmembrane count | Protein classification Cancer-related genesDisease related genesEnzymesFDA approved drug targetsMetabolic proteinsPredicted intracellular proteins |
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40Basic Information10
Protein Names
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PI3-kinase subunit gamma) (PI3K-gamma) (PI3Kgamma) (PtdIns-3-kinase subunit gamma) (EC 2.7.1.137) (EC 2.7.1.153) (EC 2.7.1.154) (Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma) (PtdIns-3-kinase subunit p110-gamma) (p110gamma) (Phosphoinositide-3-kinase catalytic gamma polypeptide) (Serine/threonine protein kinase PIK3CG) (EC 2.7.11.1) (p120-PI3K)
Protein Class (6)
Cancer-related genesDisease related genesEnzymesFDA approved drug targetsMetabolic proteinsPredicted intracellular proteins
Protein Function (7)
- Cancer-related genes:Mutational cancer driver genes
- Predicted intracellular proteins
- Kinases:Atypical kinases
- ENZYME proteins:Transferases
- Enzymes
- Disease related genes
- FDA approved drug targets:Small molecule drugs
Ensembl
Entrez Gene Symbol
Gene Description
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma
Chromosome
7
Position
106865278-106908980
Supporting publications (n)
5
EVMP confidence score
0.50
Function & Pathway7
Protein Function (7)
- Cancer-related genes:Mutational cancer driver genes
- Predicted intracellular proteins
- Kinases:Atypical kinases
- ENZYME proteins:Transferases
- Enzymes
- Disease related genes
- FDA approved drug targets:Small molecule drugs
Cellular Component (6)
Molecular Function (11)
- GO:0004672 protein kinase activity
- GO:0005515 protein binding
- GO:0005524 ATP binding
- GO:0016301 kinase activity
- GO:0016303 1-phosphatidylinositol-3-kinase activity
- GO:0035005 1-phosphatidylinositol-4-phosphate 3-kinase activity
- GO:0042802 identical protein binding
- GO:0044024 histone H2AS1 kinase activity
- GO:0046875 ephrin receptor binding
- GO:0046934 1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity
Page 1 of 2
Biological Process (3)
KEGG (14)
- hsa00562 Inositol phosphate metabolism
- KEGG:hsa01100 Metabolic pathways
- KEGG:hsa04022 cGMP-PKG signaling pathway
- KEGG:hsa04062 Chemokine signaling pathway
- KEGG:hsa04072 Phospholipase D signaling pathway
- KEGG:hsa04151 PI3K-Akt signaling pathway
- KEGG:hsa04261 Adrenergic signaling in cardiomyocytes
- KEGG:hsa04371 Apelin signaling pathway
- KEGG:hsa04611 Platelet activation
- KEGG:hsa04725 Cholinergic synapse
Page 1 of 2
Reactome (22)
- R-hsa-1280218 adaptive immune system
- R-hsa-389357 cd28 dependent pi3k akt signaling
- R-hsa-2219530 constitutive signaling by aberrant pi3k in cancer
- R-hsa-389356 co stimulation by cd28
- R-hsa-9927354 co stimulation by icos
- R-hsa-5663202 diseases of signal transduction by growth factor receptors and second messengers
- R-hsa-9027276 erythropoietin activates phosphoinositide 3 kinase pi3k
- R-hsa-114604 gpvi mediated activation cascade
- R-hsa-392451 g beta gamma signalling through pi3kgamma
- R-hsa-397795 g protein beta gamma signalling
Page 1 of 3
Mediation Categories (5)
Clinical-translation mediationFusion and delivery mediationImmune mediationMetabolism mediationReceptor-signaling mediation
Relations & Evidence42
Enzyme-Mediated Modification (3)
3 records.
| Substrate Gene Symbol | Enzyme Gene Symbol | Enzyme UniProt ID | Residue Type | Residue Offset | Modification | Database | References |
|---|---|---|---|---|---|---|---|
| PIK3CG | PRKACA | P17612 | T | 1,024 | phosphorylation | PhosphoSite | |
| PIK3CG | PRKCB | P05771 | S | 582 | phosphorylation | Sparser_ProtMapperProtMapperREACH_ProtMapperPhosphoSitePhosphoSite_ProtMapper | ProtMapper:23824069 |
| PIK3CG | PRKG1 | Q13976 | S | 1,101 | phosphorylation | KEA | KEA:17570479 |
Ligand-Receptor Signaling (11)
11 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| receptor | receptor | scConnect | No | Yes | No | No | No |
Page 2 of 2Previous
Regulatory Interaction Network (25)
25 records.
Page 1 of 3Next
Protein Complex Composition (2)
2 records.
Isolation & Detection Technology (1)
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Differential Ultracentrifugation | Mass spectrometry | 1 | 38321535 |
Sequence, Structure & Domains11
Sequences
Length
1,102
Mass
126,454
Sequence
MELENYKQPVVLREDNCRRRRRMKPRSAAASLSSMELIPIEFVLPTSQRKCKSPETALLHVAGHGNVEQMKAQVWLRALETSVAADFYHRLGPHHFLLLYQKKGQWYEIYDKYQVVQTLDCLRYWKATHRSPGQIHLVQRHPPSEESQAFQRQLTALIGYDVTDVSNVHDDELEFTRRGLVTPRMAEVASRDPKLYAMHPWVTSKPLPEYLWKKIANNCIFIVIHRSTTSQTIKVSPDDTPGAILQSFFTKMAKKKSLMDIPESQSEQDFVLRVCGRDEYLVGETPIKNFQWVRHCLKNGEEIHVVLDTPPDPALDEVRKEEWPLVDDCTGVTGYHEQLTIHGKDHESVFTVSLWDCDRKFRVKIRGIDIPVLPRNTDLTVFVEANIQHGQQVLCQRRTSPKPFTEEVLWNVWLEFSIKIKDLPKGALLNLQIYCGKAPALSSKASAESPSSESKGKVQLLYYVNLLLIDHRFLLRRGEYVLHMWQISGKGEDQGSFNADKLTSATNPDKENSMSISILLDNYCHPIALPKHQPTPDPEGDRVRAEMPNQLRKQLEAIIATDPLNPLTAEDKELLWHFRYESLKHPKAYPKLFSSVKWGQQEIVAKTYQLLARREVWDQSALDVGLTMQLLDCNFSDENVRAIAVQKLESLEDDDVLHYLLQLVQAVKFEPYHDSALARFLLKRGLRNKRIGHFLFWFLRSEIAQSRHYQQRFAVILEAYLRGCGTAMLHDFTQQVQVIEMLQKVTLDIKSLSAEKYDVSSQVISQLKQKLENLQNSQLPESFRVPYDPGLKAGALAIEKCKVMASKKKPLWLEFKCADPTALSNETIGIIFKHGDDLRQDMLILQILRIMESIWETESLDLCLLPYGCISTGDKIGMIEIVKDATTIAKIQQSTVGNTGAFKDEVLNHWLKEKSPTEEKFQAAVERFVYSCAGYCVATFVLGIGDRHNDNIMITETGNLFHIDFGHILGNYKSFLGINKERVPFVLTPDFLFVMGTSGKKTSPHFQKFQDICVKAYLALRHHTNLLIILFSMMLMTGMPQLTSKEDIEYIRDALTVGKNEEDAKKYFLDQIEVCRDKGWTVQFNWFLHLVLGIKQGEKHSA
3D Structural Models
Turn
537..540; 707..709; 722..724; 775..778; 857..859; 956..958; 976..979; 998..1000; 1042..1045; 1055..1058; 1090..1092
Helix
70..81; 83..89; 115..118; 119..128; 145..158; 165..167; 172..179; 181..190; 193..198; 209..212; 213..215; 241..243; 246..252; 256..259; 267..269; 287..289; 291..298; 313..316; 329..331; 336..339; 354..356; 420..422; 499..502; 549..560; 569..577; 579..582; 586..588; 589..593; 601..612; 615..618; 624..630; 638..648; 653..666; 667..669; 676..687; 689..705; 710..721; 726..751; 761..774; 798..800; 838..856; 888..895; 906..914; 918..941; 949..951; 965..970; 989..994; 1004..1021; 1024..1038; 1046..1054; 1061..1078; 1081..1085
Beta Strand
41..44; 55..58; 64..66; 96..108; 134..139; 169..171; 216..218; 220..226; 229..235; 263..265; 271..274; 283..285; 303..308; 346..348; 351..353; 359..369; 375..377; 380..391; 393..398; 406..419; 428..434; 462..469; 473..475; 478..483; 484..486; 511..513; 515..520; 563..565; 632..634; 671..674; 755..757; 783..785; 788..796; 806..808; 811..818; 819..821; 828..836; 869..873; 876..880; 885..887; 898..900; 915..917; 952..955; 960..962; 1039..1041
3D Structure
Electron microscopy (2); X-ray crystallography (105)
Domain & Motif Annotations
Domain (FT)
34..141; PI3K-ABD; 217..309; PI3K-RBD; 357..521; C2 PI3K-type; 541..723; PIK helical; 797..1080; PI3K/PI4K catalytic
Region
803..809; G-loop; 943..951; Catalytic loop; 962..988; Activation loop
Protein Families
PI3/PI4-kinase family
Sequence Similarities
Belongs to the PI3/PI4-kinase family.
Clinical Relevance6
Disease Involvement (3)
Cancer-related genesDisease variantFDA approved drug targets
Related Diseases (33)
COVID-19Follicular lymphomaAdrenal cancerAsthmaBacterial infectionB-cell lymphomaBCR-ABL1-negative chronic myeloid leukaemiaBladder cancerBrain cancerBreast cancerCardiovascular diseaseCentral nervous system diseaseColorectal cancerDiffuse large B-cell lymphomaEndometrial cancerHead and neck cancerInnate/adaptive immunodeficiencyLiver cancerLymphomaMalignant haematopoietic neoplasmMature B-cell leukaemiaMelanomaMetastatic lymph node neoplasmMyelodysplastic syndromeMyocardial infarctionPainPeritoneal cancerPleural mesotheliomaPostoperative inflammationProstate cancerRheumatoid arthritisSolid tumour/cancerType 2 diabetes mellitus
Biomarker
Phase 2; Approved; Phase 1; Investigative; Phase 1/2; Phase 3; Terminated; Discontinued in Phase 2
Drug Targets
FDA approved drug targets
Drugs (130)
PHENYLEPHRINESF1126INSULIN, REGULAR, HUMANVOXTALISIBNULLPI3K P110BETA/DELTA INHIBITOR KA2237TENALISIBPACLITAXELADENOVIRUS VECTORPAXALISIBPILARALISIBGEDATOLISIBBENZO(A)PYRENE-7,8-DIOL 9,10-EPOXIDEMELATONINFAS LIGANDDACTOLISIBPICTILISIBLIOTHYRONINEPF-04691502IONOMYCINPERIFOSINECLOZAPINEINDOLE-3-CARBINOLFRAMYCETINRECOMBINANT HEREGULINRAS INHIBITORFIMEPINOSTATHEPARINCOPANLISIBMANNITOLIH636 GRAPE SEED PROANTHOCYANIDIN EXTRACTESTRONERECOMBINANT CD40-LIGANDXL765SONOLISIBTG100-115DS-7423SF-1126MPAEMODININTERLEUKIN-11VINCRISTINESELECTIVE ESTROGEN RECEPTOR MODULATOROMIPALISIBTROGLITAZONERECILISIBBUPARLISIBDOXORUBICIN HYDROCHLORIDEALDESLEUKINGP-120 ANTIGENPICEATANNOLFGF-1BORTEZOMIBINFIGRATINIBLACTOSELOVASTATINATORVASTATIN CALCIUM TRIHYDRATELENOGRASTIMVS-5584GLUCAGON (RDNA)THERAPEUTIC GONADOTROPINPROGESTINPTHRPRECOMBINANT THYROID-STIMULATING HORMONEAZD-8186DUVELISIBTYRPHOSTIN A25CYCLOSPORINEBRAIN-DERIVED NEUROTROPHIC FACTORPANULISIBWX-037ANTIESTROGENIL-4C5AZSTK474RITUXIMABHYDROGEN PEROXIDEALTEPLASEINAVOLISIBIZORLISIBEGANELISIBGSK-1059615PI-103CH-5132799BUPARLISIB HYDROCHLORIDERALOXIFENE HYDROCHLORIDEPAN-PI3K INHIBITOR CLR457COLCHICINEBIMIRALISIBPI3K INHIBITOR BGT226UMBRALISIBBERZOSERTIBISOPROTERENOLPI3K/MTOR KINASE INHIBITOR PF-04691502PWT-33587GSK-2636771FULVESTRANTDAIDZEINIMATINIBALPELISIBZSTK-474TASELISIBRIGOSERTIBOCTREOTIDE ACETATEPUQUITINIBSULFORAPHANECAPTOPRILCAL-263APITOLISIBANTI-ANDROGENMTOR INHIBITORROSIGLITAZONETHEAFLAVINENZASTAURINRP-6530RETINOIC ACID AGENTFLUDARABINESELENIUMRECOMBINANT VASCULAR ENDOTHELIAL GROWTH FACTORSIMVASTATINBGT-226AZD-6482SAMOTOLISIBFLUORODEOXYGLUCOSE F18OXIDOPAMINEZINC SULFATE ANHYDROUSQUERCETINBDNFRECOMBINANT CHEMOKINEIOPOFOSINE
Antibody
Supporting Publications5
| PMID | Title | Abstract |
|---|---|---|
| 27821849 | Detailed Analysis of Protein Topology of Extracellular Vesicles-Evidence of Unconventional Membrane Protein Orientation. | No abstract available |
| 31382537 | An Insight into the Proteome of Uveal Melanoma-Derived Ectosomes Reveals the Presence of Potentially Useful Biomarkers. | No abstract available |
| 34815502 | The von Willebrand factor stamps plasmatic extracellular vesicles from glioblastoma patients. | No abstract available |
| 36736734 | Extracellular vesicle proteomics and phosphoproteomics identify pathways for increased risk in patients hospitalized with COVID-19 and type 2 diabetes mellitus. | No abstract available |
| 38716512 | Assessment of urine sample collection and processing variables for extracellular vesicle-based proteomics. | No abstract available |